Academic Journal
Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study
| العنوان: | Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study |
|---|---|
| المؤلفون: | Fortea, Juan, Vilaplana, Eduard, Carmona-Iragui, Maria, Benejam, Bessy, Videla, Laura, Barroeta, Isabel, Fernández, Susana, Altuna, Miren, Pegueroles, Jordi, Montal, Víctor, Valldeneu, Silvia, Giménez, Sandra, González-Ortiz, Sofía, Muñoz, Laia, Estellés, Teresa, Illán-Gala, Ignacio, Belbin, Olivia, Camacho, Valle, Wilson, Liam Reese, Annus, Tiina, Osorio, Ricardo S., Videla, Sebastián, Lehmann, Sylvain, Holland, Anthony, G., Alcolea, Daniel, Clarimón, Jordi, Zaman, Shahid, Blesa, Rafael, Lleó, Alberto |
| المساهمون: | Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona (UAB), IMIM-Hospital del Mar, Generalitat de Catalunya = Generalidad de Cataluña = Government of Catalonia = Généralité de Catalogne, University of Cambridge UK (CAM), New York University Langone Medical Center (NYU Langone Medical Center), NYU System (NYU), Universitat de Barcelona (UB), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Institut des Neurosciences de Montpellier (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Instituto de Salud Carlos III, Fundació Bancaria La Caixa, Fundació La Marató de TV3, Medical Research Council, and National Institutes of Health. |
| المصدر: | ISSN: 0140-6736. |
| بيانات النشر: | CCSD Elsevier |
| سنة النشر: | 2020 |
| المجموعة: | Université de Montpellier: HAL |
| مصطلحات موضوعية: | MESH: Adult, MESH: Alzheimer Disease, MESH: Cross-Sectional Studies, MESH: Down Syndrome, MESH: Fluorodeoxyglucose F18, MESH: Humans, MESH: Magnetic Resonance Imaging, MESH: Middle Aged, MESH: Neurofilament Proteins, MESH: Positron-Emission Tomography, MESH: Prevalence, MESH: Spain, MESH: United Kingdom, MESH: tau Proteins, MESH: Amyloid beta-Peptides, MESH: Amyloidosis, MESH: Apolipoproteins E, MESH: Biomarkers, MESH: Case-Control Studies, MESH: Cognitive Dysfunction, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health |
| الوصف: | International audience ; Background: Alzheimer's disease and its complications are the leading cause of death in adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with Down syndrome, but the natural history of biomarker changes in Down syndrome has not been established. We characterised the order and timing of changes in biomarkers of Alzheimer's disease in a population of adults with Down syndrome.Methods: We did a dual-centre cross-sectional study of adults with Down syndrome recruited through a population-based health plan in Barcelona (Spain) and through services for people with intellectual disabilities in Cambridge (UK). Cognitive impairment in participants with Down syndrome was classified with the Cambridge Cognitive Examination for Older Adults with Down Syndrome (CAMCOG-DS). Only participants with mild or moderate disability were included who had at least one of the following Alzheimer's disease measures: apolipoprotein E allele carrier status; plasma concentrations of amyloid β peptides 1-42 and 1-40 and their ratio (Aβ1-42/1-40), total tau protein, and neurofilament light chain (NFL); tau phosphorylated at threonine 181 (p-tau), and NFL in cerebrospinal fluid (CSF); and one or more of PET with 18F-fluorodeoxyglucose, PET with amyloid tracers, and MRI. Cognitively healthy euploid controls aged up to 75 years who had no biomarker abnormalities were recruited from the Sant Pau Initiative on Neurodegeneration. We used a first-order locally estimated scatterplot smoothing curve to determine the order and age at onset of the biomarker changes, and the lowest ages at the divergence with 95% CIs are also reported where appropriate.Findings: Between Feb 1, 2013, and June 28, 2019 (Barcelona), and between June 1, 2009, and Dec 31, 2014 (Cambridge), we included 388 participants with Down syndrome (257 [66%] asymptomatic, 48 [12%] with prodromal Alzheimer's disease, and 83 [21%] with Alzheimer's disease dementia) and 242 euploid controls. CSF Aβ1-42/1-40 and plasma NFL values ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/32593336; PUBMED: 32593336; PUBMEDCENTRAL: PMC7322523; WOS: 000547825600016 |
| DOI: | 10.1016/S0140-6736(20)30689-9 |
| الاتاحة: | https://hal.science/hal-03608832 https://hal.science/hal-03608832v1/document https://hal.science/hal-03608832v1/file/1-s2.0-S0140673620306899-main.pdf https://doi.org/10.1016/S0140-6736(20)30689-9 |
| Rights: | http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.D7DADBD9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S0140-6736(20)30689-9 |
|---|